UBM Medica Corporate Officers

Article

Henry ElkingtonCEO, UBM Medica Ltd, UKPatrick McAleenanCFO, UBM Medica Ltd, UKSally ShanklandCEO, UBM Medica USASteve ResnickVP, Finance Director, USAJulia MurphyVP, Director of Human Resources, USAPamela L. Moore, PhDEVP, Content & Strategy, USAMorgan KelseyVP, Technology, USA

Henry Elkington
CEO, UBM Medica Ltd, UK

Patrick McAleenan
CFO, UBM Medica Ltd, UK

Sally Shankland
CEO, UBM Medica USA

Steve Resnick
VP, Finance Director, USA

Julia Murphy
VP, Director of Human Resources, USA

Pamela L. Moore, PhD
EVP, Content & Strategy, USA

Morgan Kelsey
VP, Technology, USA

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content